



FILE COPY

SHEET 1 of 6

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
MDP	B1	WO 91/09955	7/11/91	PCT				
↑	B2	WO 92/20808	11/26/92	PCT				
	B3	WO 93/11236	6/10/93	PCT				
	B4	WO 94/12650	6/9/94	PCT				
↓	B5	WO 97/09433	11/13/97	PCT				
MDP	B6	EP 0867508	9/30/98	EPO				


EXAMINER

MICHAEL PM

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Wdp	C1	Anderson, Human gene therapy, <i>Nature</i> , 392 (supp.): 25-30 (April 30, 1998)
↑	C2	Aujame <i>et al.</i> , High affinity human antibodies by phage display, <i>Human Antibodies</i> , 8(4):155-168 (1997)
	C3	Ausubel <i>et al.</i> , <i>Current Protocols in Molecular Biology</i> , John Wiley & Sons pp. 6.0.3-6.4.10 (1994)
	C4	Böhm <i>et al.</i> Regulatory mechanisms that modulate signalling by G-protein-coupled receptors, <i>Biochem. J.</i> 322: 1-18 (1997)
	C5	Boulton <i>et al.</i> , ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF, <i>Cell</i> , 65: 663-75 (1991)
	C6	Bruggemann and Neuberger, Strategies for expressing human antibody repertoires in transgenic mice. <i>Immunol. Today</i> , 17(8):391-97 (1996)
	C7	Bruggemann and Taussig, Production of human antibody repertoires in transgenic mice, <i>Curr. Opin. Biotechnol.</i> , 8: 455-58 (1997)
	C8	Capecchi, Altering the genome by homologous recombination, <i>Science</i> , 244: 1288-1292 (1989)
	C9	Choo <i>et al.</i> , Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers, <i>J. Mol. Biol.</i> 273: 525-532 (1997)
	C10	Cobbold and Lee, Aequorin measurements of cytoplasmic free calcium, In <i>Cellular Calcium: A Practical Approach</i> , Ch 2 pp. 55-81 (1991)
	C11	Dayhoff, <i>Atlas of Protein Sequence and Structure</i> Vol.5, p. 124 (1972)
	C12	Dooley <i>et al.</i> , Binding and <i>in vitro</i> activities of peptides with high affinity for the nociceptin/orphanin FQ Receptor, ORL1, <i>J. Pharm. Exp. Therap.</i> , 283: 735-741 (1997)
Wdp	C13	Dunlop <i>et al.</i> , Characterization of 5-HT _{1A} receptor functional coupling in cells expressing the human 5-HT _{1A} receptor as assessed with the cytosensor microphysiometer, <i>J. Pharm. Tox. Meth.</i> , 40(1): 47-55 (1998)

EXAMINER

MICHAEL PHEL

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

WDP	C14	Foote and Winter, Antibody framework residues affecting the conformation of the hypervariable loops, <i>J. Mol. Biol.</i> , 224: 487-499 (1992)
↑	C15	Frandsen and Krishna, A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues, <i>Life Sciences</i> , 18: 529-542 (1976)
	C16	Friedmann, Progress toward human gene therapy, <i>Science</i> , 244: 1275-1281 (1989)
	C17	George <i>et al.</i> , Evaluation of a CRE-directed luciferase reporter gene assay as an alternative to measuring cAMP accumulation, <i>Journal of Biomolecular Screening</i> , 2(4): 235-240 (1997)
	C18	Greisman and Pabo. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites, <i>Science</i> , 275: 657-661 (1997)
	C19	Harlow and Lane, <i>Antibodies a Laboratory Manual</i> , Cold Springs Harbor Laboratory Ch.6 (1988)
	C20	Hoogenboom, Designing and optimizing library selection strategies for generating high affinity antibodies, <i>Trends in Biotechnology</i> , 15: 62-70 (1997)
	C21	Jones <i>et al.</i> , Replacing the complementarity-determining regions in a human antibody with those from a mouse, <i>Nature</i> , 321: 522-525 (1986)
	C22	Kanterman <i>et al.</i> , Transfected D ₂ dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells, <i>Molecular Pharmacology</i> , 39: 364-369 (1991)
↓	C23	Kettleborough <i>et al.</i> , Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation, <i>Protein Engin</i> , 4: 773-783 (1991)
WDP	C24	Kim et al. Design of TATA box-binding protein/zinc finger fusions for targeted regulation of gene expression, <i>Proc. Natl. Acad. Sci. (USA)</i> , 94: 3616-3620 (1997)


EXAMINER

MICHAEL PAN

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MDD	C25	Kowal <i>et al.</i> , A [³⁵ S]GTPγS binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4, <i>Neuropharmacology</i> , 37: 179-187 (1998)
↑	C26	Kuntzweiler <i>et al.</i> , Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR, <i>Drug Development Research</i> , 44(1): 14-20 (1998)
	C27	Lajiness <i>et al.</i> , D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations, <i>J. Pharm. Exp. Therap.</i> , 267(3): 1573-1581 (1993)
	C28	Lehninger, <i>Biochemistry</i> 2d, Worth Publishers pp.71-77 (1975)
	C29	Liu <i>et al.</i> , Design of polydactyl zinc-finger proteins for unique addressing within complex genomes, <i>Proc. Natl. Acad. Sci. (USA)</i> , 94: 5525-5530 (1997)
	C30	McColl <i>et al.</i> , Structure-based design of an RNA-binding zinc finger, <i>Proc. Natl. Acad. Sci. (USA)</i> , 96: 9521-9526 (1999)
	C31	Miller. Human gene therapy comes of age, <i>Nature</i> , 357: 455-460 (1992)
	C32	Morrison and Oi, Genetically engineered antibody molecules, <i>Adv. Immunol.</i> 44: 65-92 (1989)
	C33	Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <i>Molecular Immunology</i> 28(4/5): 489-98 (1991)
	C34	Parodi <i>et al.</i> , A consensus procedure for predicting the location of α-helical transmembrane segments in proteins, <i>Comput. Appl. Biosci.</i> 10(5): 527-535 (1994)
↓	C35	Radar <i>et al.</i> , Phage display of combinatorial antibody libraries, <i>Curr. Opin. Biotechnol.</i> , 8: 503-508 (1997)
MDD	C36	Riechmann <i>et al.</i> , Reshaping human antibodies for therapy, <i>Nature</i> , 332: 323-327 (1988)


EXAMINER

MICHAEL PARK

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

WAP	C37	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Springs Harbor Laboratory pp. 9.47-9.51 (1989)
↑	C38	Segal <i>et al.</i> , Toward controlling gene expression at will: Selection and design of zinc finger domains recognizing each 5'-GNN-3' DNA target sequences, <i>Proc. Natl. Acad. Sci. (USA)</i> , 96: 2758-2763 (1999)
	C39	Stables <i>et al.</i> , A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor, <i>Analytical Biochemistry</i> , 252: 115-126 (1997)
	C40	Stratowa <i>et al.</i> , Use of a luciferase reporter system for characterizing G-protein-linked receptors, <i>Curr. Opin. Biotechnol.</i> , 6: 574-581 (1995)
	C41	Strosberg, Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins, <i>Eur. J. Biochem.</i> 196: 1-10 (1991)
	C42	Sutherland <i>et al.</i> , Some aspects of the biological role of adenosine 3', 5'-monophosphate (cyclic AMP), <i>Circulation</i> , 37: 279-306 (1968)
	C43	Tempest <i>et al.</i> , Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection <i>in vivo</i> , <i>Bio/Technology</i> , 9: 266-71 (1991)
	C44	Wu <i>et al.</i> , Building zinc fingers by selection: Toward a therapeutic application. <i>Proc. Natl. Acad. Sci. (USA)</i> , 92: 344-348 (1995)
	C45	Verhoeyen <i>et al.</i> , Reshaping human antibodies: grafting an antilysozyme activity, <i>Science</i> , 239: 1534-36 (1988)
	C46	Verma, Gene therapy, <i>Scientific American</i> , 63: 68-84 (1990)
	C47	Drutel <i>et al.</i> , Cloning of OL1, a putative olfactory receptor and its expression in the developing rat heart, <i>Receptors and Channels</i> 3: 33-40 (1995)
↓	C48	Fan <i>et al.</i> , Identification of seven new human MHC class I region genes around the HLA-F locus, <i>Immunogenetics</i> 44: 97-103 (1996)
WAP	C49	Krautwurst <i>et al.</i> , Identification of ligands for olfactory receptors by functional expression of a receptor library, <i>Cell</i> 95: 917-926 (1998)


EXAMINER

MICHAEL PBL

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6202NCPSerial No.
09/634,109Applicant
Vogeli et al.Filing Date
Aug. 8, 2000Group
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

WDP	C50	Marchese <i>et al.</i> , Mapping studies of two G protein-coupled receptor genes: an amino acid difference may confer a functional variation between a human and rodent receptor, <i>Biochem. Biophys. Res. Comm.</i> 205: 1952-1958 (1994)
↑	C51	Marchese et al., Cloning of human genes encoding novel G protein-coupled receptors, <i>Genomics</i> , 23: 609-618 (1994)
↓	C52	Genebank Accession No.: L35475, Human olfactory receptor-like gene, deposited by Fan, W.F. dated 25 November 1998
↓	C53	Genebank Accession No.: AF102537, <i>Mus musculus</i> olfactory receptor G7 mRNA, deposited by Krautwurst <i>et al.</i> , dated 08 February 1999.
WDP	C54	EMBL Accession No. Q9Z1U2 <i>Mus musculus</i> olfactory receptor G3 (fragment) deposited by Krautwurst <i>et al.</i> , dated 01 May 1999.

EXAMINER

MICHAEL VAN

DATE CONSIDERED

6-25-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.